Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.64USD
12 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.64
Open
$0.67
Day's High
$0.67
Day's Low
$0.64
Volume
131,515
Avg. Vol
153,353
52-wk High
$1.83
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Bioline Rx Ltd ::BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML.BIOLINE RX-RESULTS SHOW THAT COMBINATION OF BL-8040 WITH HIGH-DOSE ARA-C SIGNIFICANTLY IMPROVED OVERALL SURVIVAL VERSUS HISTORICAL DATA OF HIDAC MONOTHERAPY.  Full Article

BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - BioLine Rx Ltd :BioLineRx reports third quarter 2017 financial results.BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​.  Full Article

BioLine RX says ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - BioLine RX Ltd :BioLine RX Ltd - ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 million - SEC filing.  Full Article

BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Bioline Rx Ltd :BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration.Bioline RX Ltd - ‍Genentech commenced a phase 1b/2 study for treatment of gastric cancer with BL-8040 in combination with atezolizumab​.  Full Article